N/A
N=68
Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles
Virus Diseases · Herpes Zoster
Bottom Line
View on ClinicalTrials.gov: NCT00921934 ↗Enrolled (actual)
68
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcome: Primary: Change of Pain Measured by VAS — 5.8; 2.2; 0.6; 1.2 pain intensity
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
- Primary completion
- Dec 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change of Pain Measured by VAS |
5.8; 2.2; 0.6; 1.2 | — |
Summary
Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders. Therefore, a sufficient treatment of oxidative stress may be of benefit for the patient to prevent further diseases.
Shingles (herpes zoster infection) have been successfully treated with antioxidative substances like high-dose vitamin C for ages. Not only the acute symptoms can be diminished by high-dose vitamin C. Even long-term sequelae, like painful post-herpetic neuropathy, may be mitigated or even fully avoided.
Eligibility Criteria
Due to the design of an Observational Cohort Study, no inclusion or exclusion criteria are named. The included patient group is described under "Cohort / Group".
Observational Criteria:
- adult patients
- acute viral infection (especially herpes zoster)
- Primary Care patient
- eligible for add-on therapy with vitamin C
- willingness to provide pseudonymized data to the Sponsor
Data sourced from ClinicalTrials.gov (NCT00921934). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.